Patent classifications
A61K9/5031
METHOD FOR COATING AND DRYING HETEROGENOUS STEM CELL DERIVED EXTRA-CELLULAR VESICLES
Coated and Dried extracellular vesicles (EVs) represent an ideal method for preservation and increasing the shelf life-time of the invention making it ready to use on time and on variety of species overcoming the previous challenges on isolation and preservation and undesirable immune responses. The invention compromises a coated freeze dried stem cells derived EVs that are ready for use to Stimulate/accelerate healing of soft/hard tissues, can be reconstituted in multiple forms and shapes and stimulated by Laser. The nature of the invention is a heterogenous and/or Xenogenous EVs which can overcome the challenges of individual and/or species diseases and immune reactions.
Composition for promoting wound healing and preparing method thereof
The present disclosure relates to a composition sustainable-releasing hydrogen sulfide for promoting wound healing and the method for preparing the same. The composition for promoting wound healing comprises a carrier and a plurality of hydrogen sulfide sustained releasing microspheres, wherein the hydrogen sulfide sustained releasing microspheres comprise a hydrophobic polymer, a surfactant and sodium hydrosulfide.
Particles for Targeted Delivery and Uses in Managing Bleeding or Blood Clotting
This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.
BIODEGRADABLE MICROCAPSULES
A reloadable microcapsule contains a microcapsule core and a microcapsule wall encapsulating the microcapsule core. The microcapsule core contains a hydrophobic core solvent and a hydrophilic core solvent, and the microcapsule wall, formed of an encapsulating polymer, is permeable to the hydrophilic core solvent. Also disclosed are methods of preparing the reloadable microcapsule and consumer products having the microcapsules.
Spherical microparticles with polyester walls
The present invention relates to compositions of spherical microparticles composed of a wall material and at least one cavity that comprises a gas and/or a liquid, which have pores on the surface thereof, wherein the spherical microparticles have a mean particle diameter of 10-600 μm and wherein at least 80% of those microparticles, the particle diameter of which does not deviate from the mean particle diameter of the microparticles of the composition by more than 20%, each have on average at least 10 pores, the diameter of which is in the range from 1/5000 to ⅕ of the mean particle diameter, and, furthermore, the diameter of each of these pores is at least 20 nm, wherein the wall material consists of a composition comprising at least one aliphatic-aromatic polyester, and the wall material has a solubility at 25° C. of at least 50 g/l in dichloromethane, a method for the preparation thereof and also the use thereof.
Reloadable microcapsules
A reloadable microcapsule contains a microcapsule core and a microcapsule wall encapsulating the microcapsule core. The microcapsule core contains a hydrophobic core solvent and a hydrophilic core solvent, and the microcapsule wall, formed of an encapsulating polymer, is permeable to the hydrophilic core solvent. Also disclosed are methods of preparing the reloadable microcapsule and consumer products having the microcapsules.
COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER
The disclosure provides compounds and method useful for modulating gp130 biological activity. The disclosure also provides methods and compositions for treating disease and disorders associated with gp130 activity, particularly those associated with inflammation.
Delivery devices and methods for making the same
In an example of a method for making a pulsatile delivery device, one type of charges are generated on a polymeric layer, and charges opposite the one type of charges are generated on a delivery layer including a film forming material and a predetermined substance dispersed throughout the film forming material. The charged polymeric and delivery layers are placed into contact to form a bi-layer structure. A stack with at least two bi-layer structures is formed so that the polymeric layers and the delivery layers are alternating throughout the stack. The stack is sealed so that one of the polymeric layers remains exposed.
Bilirubin derivative-based diagnostic and therapeutic ultrasound contrast agent
Provided is a bilirubin derivative-based ultrasound contrast agent for diagnosis and treatment. The fine particles including the bilirubin derivative are sensitive to reactive oxygen species (ROS), bind with hydrophobic drugs, and can effectively chelate metals such as iron oxide nanoparticles. Therefore, the fine particle of the present invention can be used as an ultrasound contrast agent for diagnosis, as a magnetic resonance imaging contrast agent, or as a carrier for hydrophobic drugs or platinum-based drugs.
PHARMACEUTICAL COMPOSITION COMPRISING SUSTAINED-RELEASE MICROSPHERES INCLUDING GLP-1 ANALOGUE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
The present invention relates to a pharmaceutical composition useful for prevention or treatment of diabetes, beta-cell function preservation, high blood pressure, hyperlipidemia, obesity, non-alcoholic steatohepatitis or neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, as it comprises a sustained-release microsphere comprising semaglutide, a pharmaceutically acceptable salt, hydrate or solvate thereof, and thereby, it can effectively inhibit fatal side-effects by preventing initial burst of a drug and comprise a high content of drug compared to a particle size, and therefore, it can minimize the patient's pain and inflammatory reaction that may occur during administration.